researcher comment: positive os data for osimertinib in flaura trial | suresh ramalingam
Published 4 years ago • 236 plays • Length 1:50Download video MP4
Download video MP3
Similar videos
-
6:50
osimertinib: a potential new standard of care for advanced egfr-mutated nsclc | suresh ramalingam
-
2:04
dr. suresh ramalingam on frontline osimertinib data in egfr nsclc
-
7:00
flaura trial: impact of os data in advanced nsclc
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
2:20
adjuvant osimertinib in resected egfrm nsclc: the os data from the adaura trial
-
8:55
suresh ramalingam: osimertinib vs comparator egfr-tki 1st-line in egfrm advanced nsclc (flaura)
-
0:48
investigating osimertinib for brain activity in egfr-mutated lung cancer
-
10:59
lung cancer stage 4: egfr l858r & e709k positive after 13months of taking osimertinib-tagrisso
-
4:38
new agents for egfr nsclc: osimertinib and beyond
-
3:57
sequencing with osimertinib in egfr-positive nsclc
-
1:40
dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
-
1:45
dr. ramalingam on the use of osimertinib in clinical trial and real-world settings
-
2:34
dr. ramalingam on flaura findings in egfr-mutant nsclc
-
2:09
dr. ramalingam on flaura trial results in egfr-mutant nsclc
-
1:02
examining data for osimertinib in egfr lung cancer
-
6:06
osimertinib, the standard for egfr nsclc
-
9:27
post-hoc analysis of sequential afatinib and osimertinib in nsclc patients
-
2:42
safety and efficacy data for osimertinib
-
9:49
osimertinib as frontline therapy for egfr-positive nsclc
-
1:34
dr. ramalingam on new data for egfr inhibitors for lung cancer
-
1:36
comment: front-line osimertinib significantly lengthens overall survival in egfr-mutation positi...